摘要:
The present invention concerns novel compounds represented by the Formula: ##STR1## wherein: A is R.sup.1.sub.q (R.sup.3 R.sup.60 N).sub.m (Z)(NR.sup.2).sub.n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C.dbd.O or SO.sub.2 ; n is 1 with the proviso that, when Z is C.dbd.O, m is 1; X is --NH--, --CH.sub.2 --, or --OCH.sub.2 --; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R.sup.1 is H, lower alkyl, or phenyl, with the proviso that, when R.sup.1 is H, m is 1; R.sup.2, R.sup.3, R.sup.60 are each independently H, lower alkyl, or phenyl; R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are each independently hydrogen, lower alkyl, --CF.sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R.sup.2 and R.sup.7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5- or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or --CN, with the proviso that, when R.sup.7 is hydroxyl or lower alkylsulfonamido, then X is not --NH-- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R.sup.1 SO.sub.2 NR.sup.2 --), (R.sup.3 R.sup.60 NSO.sub.2 NR.sup.2 --), or (R.sup.3 R.sup.60 NCONR.sup.2 --). The invention also includes the use of the above compounds, and compositions containing them, as alpha.sub.1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.
摘要翻译:本发明涉及由下式表示的新化合物:其中:A为R 1q(R 3 R 60 N)m(Z)(NR 2)n; m和q各自为0或1,条件是当q为1时,m为0,当q为0时,m为1; Z是C = O或SO 2; n为1,条件是当Z为C = O时,m为1; X是-NH-,-CH 2 - 或-OCH 2 - ; Y是2-咪唑啉,2-恶唑啉,2-噻唑啉或4-咪唑; R 1为H,低级烷基或苯基,条件是当R 1为H时,m为1; R 2,R 3,R 60各自独立地为H,低级烷基或苯基; R4,R5,R6和R7各自独立地为氢,低级烷基,-CF3,低级烷氧基,卤素,苯基,低级烯基,羟基,低级烷基亚磺酰氨基或低级环烷基,其中R2和R7任选地可以一起形成亚烷基 或未取代或任选取代的5元或6元环中2至3个原子的亚烯基,其中环上任选取代基为卤素,低级烷基或-CN,前提条件是当R 7为羟基或低级烷基亚磺酰氨基 那么当Y是2-咪唑啉时,X不是-NH-。 所述化合物包括上述药学上可接受的盐。 在上述式A中可以是例如(R 1 SO 2 NR 2 - ),(R 3 R 60 NSO 2 NR 2 - )或(R 3 R 60 NCONR 2 - )。 本发明还包括上述化合物和含有它们的组合物作为α1A/ 1L激动剂在治疗各种疾病状态如尿失禁,鼻充血,阴茎异常勃起,抑郁,焦虑,痴呆,衰老,阿尔茨海默病,阿尔茨海默病, 注意力和认知,以及进食障碍,如肥胖,贪食症和厌食症。
摘要:
Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R′, R5 and R10 are as defined herein.
摘要:
Compounds effective as IP receptor modulators, particularly IP receptor antagonists, that are of the formula I: wherein A, R1, R2, R3 and R4 are as defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. Also disclosed are pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.
摘要:
The present invention concerns novel compounds represented by the Formula: ##STR1## wherein: A is R.sup.1.sub.q (R.sup.3 R.sup.60 N).sub.m (Z)(NR.sup.2).sub.n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C.dbd.O or SO.sub.2 ; n is 1 with the proviso that, when Z is C.dbd.O, m is 1; X is --NH--, --CH.sub.2 --, or --OCH.sub.2 --; Y is [2-imidazoline, 2-oxazolin] 2-thiazoline, [or 4-imidazole] R.sup.1 is H, lower alkyl, or phenyl, with the proviso that, when R.sup.1 is H, m is 1; R.sup.2, R.sup.3, R.sup.60 are each independently H, lower alkyl, or phenyl; R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are each independently hydrogen, lower alkyl, --CF.sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R.sup.2 and R.sup.7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5- or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or --CN, with the proviso that, when R.sup.7 is hydroxyl or lower alkylsulfonamido, then X is not --NH-- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R.sup.1 SO.sub.2 NR.sup.2 --), (R.sup.3 R.sup.60 NSO.sub.2 NR.sup.2 --), or (R.sup.3 R.sup.60 NCONR.sup.2 --). The invention also includes the use of the above compounds, and compositions containing them, as alpha.sub.1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.
摘要翻译:本发明涉及由下式表示的新化合物:其中:A为R 1q(R 3 R 60 N)m(Z)(NR 2)n; m和q各自为0或1,条件是当q为1时,m为0,当q为0时,m为1; Z是C = O或SO 2; n为1,条件是当Z为C = O时,m为1; X是-NH-,-CH 2 - 或-OCH 2 - ; Y是[2-咪唑啉,2-恶唑啉] -2-噻唑啉,[或4-咪唑] R 1是H,低级烷基或苯基,条件是当R 1是H时,m是1; R 2,R 3,R 60各自独立地为H,低级烷基或苯基; R4,R5,R6和R7各自独立地为氢,低级烷基,-CF3,低级烷氧基,卤素,苯基,低级烯基,羟基,低级烷基亚磺酰氨基或低级环烷基,其中R2和R7任选地可以一起形成亚烷基 或未取代或任选取代的5元或6元环中2至3个原子的亚烯基,其中环上任选取代基为卤素,低级烷基或-CN,前提条件是当R 7为羟基或低级烷基亚磺酰氨基 那么当Y是2-咪唑啉时,X不是-NH-。 所述化合物包括上述药学上可接受的盐。 在上述式A中可以是例如(R 1 SO 2 NR 2 - ),(R 3 R 60 NSO 2 NR 2 - )或(R 3 R 60 NCONR 2 - )。 本发明还包括上述化合物和含有它们的组合物作为α1A/ 1L激动剂在治疗各种疾病状态如尿失禁,鼻充血,阴茎异常勃起,抑郁,焦虑,痴呆,衰老,阿尔茨海默病,阿尔茨海默病, 注意力和认知,以及进食障碍,如肥胖,贪食症和厌食症。
摘要:
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein: R1, R2, and R3 are each independently in each occurrence aryl or heteroaryl; R4 is —COOH or tetrazolyl; A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and processes for their preparation.
摘要翻译:本发明涉及通常为IP受体拮抗剂并由式I表示的化合物:其中:R 1,R 2和R 3, 各自独立地为芳基或杂芳基; R 4是-COOH或四唑基; A,B,m,n和r如说明书中所定义; 或各异构体,异构体的外消旋或非外消旋混合物,或其药学上可接受的盐或溶剂合物。 本发明还涉及含有这些化合物的药物组合物,其用作治疗剂的方法及其制备方法。
摘要:
Compounds effective as IP receptor modulators, particularly IP receptor antagonists, that are of the formula I: wherein A, R1, R2, R3 and R4 are as defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. Also disclosed are pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.
摘要:
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein: R1, R2, and R3 are each independently in each occurrence aryl or heteroaryl; R4 is —COOH or tetrazolyl; A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and processes for their preparation.
摘要翻译:本发明涉及通常为IP受体拮抗剂并由式I表示的化合物:其中:R 1,R 2和R 3各自独立地在每个出现的芳基或杂芳基中; R 4, 是-COOH或四唑基; A,B,m,n和r如说明书中所定义;或各异构体,异构体的外消旋或非外消旋混合物或其药学上可接受的盐或溶剂合物。 本发明还涉及含有这些化合物的药物组合物,其用作治疗剂的方法及其制备方法。
摘要:
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein: R1, R2, and R3 are each independently in each occurrence aryl or heteroaryl; R4 is —COOH or tetrazolyl; A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and processes for their preparation.
摘要翻译:本发明涉及通常为IP受体拮抗剂并由式I表示的化合物:其中:R 1,R 2和R 3, 各自独立地为芳基或杂芳基; R 4是-COOH或四唑基; A,B,m,n和r如说明书中所定义; 或各异构体,异构体的外消旋或非外消旋混合物,或其药学上可接受的盐或溶剂合物。 本发明还涉及含有这些化合物的药物组合物,其用作治疗剂的方法及其制备方法。